S

Solumed Centrum Medyczne | Poznan, Poland

Research site
(Unclaimed)
Location
Dabrowskiego 77A, Poznan, Greater Poland, Poland

Site insights

Top conditions

Top treatments

Atogepant
JNJ-77242113
Ruxolitinib
Povorcitinib
BOTOX
Risankizumab
Dupilumab
Upadacitinib
Topiramate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 13 total trials

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting
Chronic Migraine
Episodic Migraine
Drug: Atogepant 60 mg
Locations recently updated

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo
Locations recently updated

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: JNJ-77242113
Locations recently updated

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling
Prurigo Nodularis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and...

Enrolling
Migraine
Drug: Placebo for Atogepant
Drug: Topiramate

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatmen...

Active, not recruiting
Migraine
Drug: Placebo comparator dosing
Drug: Rimegepant 75mg every other day dosing

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatm...

Enrolling
Angioedema
Hives
Drug: Placebo
Drug: Povorcitinib

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting
Episodic Migraine
Drug: Placebo
Drug: BOTOX

A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to...

Enrolling
Migraine
Drug: Placebo for Atogepant
Drug: Atogepant

Trial sponsors

AbbVie logo
Incyte logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems